Intracranial Solitary Fibrous Tumor/Hemangiopericytoma Treated with Microsurgical Resection: Retrospective Cohort Analysis of a Single-Center Experience DOI Creative Commons
Shreya Swaminathan,

Jacob Ruzevick,

Vyshak Alva Venur

et al.

Therapeutics and Clinical Risk Management, Journal Year: 2022, Volume and Issue: Volume 18, P. 901 - 912

Published: Sept. 1, 2022

To provide benchmarks for further studies of solitary fibrous tumor/hemangiopericytoma (SFT/HPC) the central nervous system (CNS), we investigated association baseline demographic, clinico-pathologic, and treatment factors with outcomes in those treated at our center.We conducted a retrospective, cohort analysis patients SFT/HPC University Washington 1990-2020. Kaplan-Meier univariable Cox analyses assessed relationships between variables local or global CNS recurrence, extraneural progression-free survival (PFS) overall (OS).Among 34 eligible patients, median duration follow-up was 79 months (range 13-318 months). Local recurrence occurred 81 m (95% CI 48-151) 47-112), respectively. Extraneural metastases 248 180-Not Reached) only grade 3 tumors. Median PFS OS were 76 CI: 47-109 months) 210 131-306 months), Univariable showed that age diagnosis associated (p = 0.01) relapse 0.01), 0.03). Gross total resection decreased 0.02) improved 0.03); peri-operative radiation 0.02).Following microsurgical SFT/HPC, is common age, extent resection, adjuvant radiation. occurs some patients. Delayed time-to-initial justifies prolonged surveillance, but optimal approaches have not been defined.

Language: Английский

Circulating Tumor DNA Minimal Residual Disease Detection of Non–Small-Cell Lung Cancer Treated With Curative Intent DOI
Bruna Pellini, Aadel A. Chaudhuri

Journal of Clinical Oncology, Journal Year: 2022, Volume and Issue: 40(6), P. 567 - 575

Published: Jan. 5, 2022

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker with the potential to improve survival outcomes for non-small-cell lung cancer (NSCLC). Multiple groups have shown ability detect MRD following curative-intent NSCLC treatment using next-generation sequencing-based assays of plasma cell-free DNA. These studies been modest in size, largely retrospective, and without thorough prospective clinical validation. Still, when restricting measurement first post-treatment timepoint assess performance ctDNA detection, they demonstrated sensitivity predicting relapse ranging between 36% 100%, specificity 71% 100%. When considering all follow-up timepoints (surveillance), including those beyond initial measurement, these assays' performances identifying from 82% 100% 70% respectively. In this manuscript, we review evidence available date regarding detection patients undergoing ongoing involving patient population.

Language: Английский

Citations

137
A clinician’s handbook for using ctDNA throughout the patient journey DOI Creative Commons
Samantha O. Hasenleithner, Michael R. Speicher

Molecular Cancer, Journal Year: 2022, Volume and Issue: 21(1)

Published: March 21, 2022

The promise of precision cancer medicine presently centers around the genomic sequence a patient's tumor being translated into timely, actionable information to inform clinical care. analysis cell-free DNA from liquid biopsy, which contains circulating (ctDNA) in patients with cancer, has proven be amenable various settings oncology. However, open questions surrounding validity and utility plasma-based analyses have hindered widespread adoption.Owing rapid evolution field, studies supporting use ctDNA as biomarker throughout journey accumulated last few years, warranting review latest status for clinicians who may employ their oncology programs. In this work, we take step back intricate coverage detection approaches described extensively elsewhere cover basic concepts practical implementation next generation sequencing (NGS)-guided biopsy. We compare relevant targeted untargeted plasma analysis, describe evidence utility, highlight value genome-wide particularly it relates early strategies discovery applications harnessing non-coding genome.The maturation biopsy application will require interdisciplinary efforts address current challenges. alike greatly benefit future its incorporation routine

Language: Английский

Citations

84
Practical recommendations for using ctDNA in clinical decision making DOI
Stacey A. Cohen, Minetta C. Liu, Alexey Aleshin

et al.

Nature, Journal Year: 2023, Volume and Issue: 619(7969), P. 259 - 268

Published: July 12, 2023

Language: Английский

Citations

82
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer DOI Creative Commons

Chris Abbosh,

Darren Hodgson, Gary J. Doherty

et al.

Trends in cancer, Journal Year: 2024, Volume and Issue: 10(7), P. 643 - 654

Published: June 4, 2024

Systemic treatment of resectable non-small cell lung cancer (NSCLC) is evolving with emerging neoadjuvant, perioperative, and adjuvant immunotherapy approaches. Circulating tumor DNA (ctDNA) detection at clinical diagnosis, during neoadjuvant therapy, or after resection may discern high-risk patients who might benefit from therapy escalation switch. This Review summarizes translational implications data supporting ctDNA-based risk determination in NSCLC outstanding questions regarding ctDNA validity/utility as a prognostic biomarker. We discuss capabilities to refine tumor-node-metastasis (TNM) staging adenocarcinoma, dynamics for identifying deriving suboptimal benefit, postoperative molecular residual disease (MRD) escalate systemic therapy. Considering differential relapse characteristics landmark MRD-negative/MRD-positive patients, we propose how integrate pathological response optimal stratification.

Language: Английский

Citations

9
Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment DOI Open Access
Giovanni Crisafulli

Genes, Journal Year: 2025, Volume and Issue: 16(1), P. 71 - 71

Published: Jan. 9, 2025

This review provides a comprehensive overview of the evolving role minimal residual disease (MRD) for patients with Colon Cancer (CC). Currently, standard care non-metastatic CC is adjuvant chemotherapy (ACT) all stage III and high-risk II following surgical intervention. Despite 5-20% improvement in long-term survival outcomes, this approach also results significant proportion receiving ACT without any therapeutic benefit being unnecessarily exposed to risks secondary side effects. underscores an unmet clinical need more precise stratification distinguish who necessitate from those can be treated surgery alone. By employing liquid biopsy, it possible discern MRD enabling categorization as MRD-positive or MRD-negative, potentially revolutionizing management ACT. aimed examine heterogeneity methodologies currently available detection, encompassing state-of-the-art technologies, their respective advantages, limitations, technological challenges multi-omic approaches that utilized enhance assay performance. Furthermore, discussion was held regarding trials employ focusing on assays used. These differences methodology, target selection, performance risk producing inconsistent may not solely reflect biological/clinical but consequence preferential use particular products studies conducted different countries. Standardization harmonization will crucial ensure revolution delivers reliable clinically actionable outcomes patients.

Language: Английский

Citations

1
The Potential Role of Circulating Tumor DNA as a Tool in the Management of Gastrointestinal Malignancies DOI

Zachary Gottschalk,

Stacey A. Cohen

Advances in Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

1
Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer DOI Open Access
Misty Dawn Shields, Kevin Chen,

Giselle Dutcher

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(16), P. 9006 - 9006

Published: Aug. 12, 2022

Advancements in the clinical practice of non-small cell lung cancer (NSCLC) are shifting treatment paradigms towards increasingly personalized approaches. Liquid biopsies using various circulating analytes provide minimally invasive methods sampling molecular content within tumor cells. Plasma-derived DNA (ctDNA), tumor-derived component cell-free (cfDNA), is most extensively studied analyte and has a growing list applications management NSCLC. As an alternative to genotyping, assessment oncogenic driver alterations by ctDNA become accepted companion diagnostic via both single-gene polymerase chain reactions (PCR) next-generation sequencing (NGS) for advanced technologies have also shown ability detect emerging mechanisms acquired resistance that evolve after targeted therapy. Furthermore, detection minimal residual disease (MRD) patients with NSCLC curative-intent may serve as prognostic potentially predictive biomarker recurrence response therapy, respectively. Finally, analysis mutational, methylation, and/or fragmentation multi-omic profiling offers potential improving early detection. In this review, we discuss role each these capacities, namely, profiling, monitoring, MRD detection,

Language: Английский

Citations

33
Strategies for improving detection of circulating tumor DNA using next generation sequencing DOI Creative Commons
R. Tébar-Martínez, Jorge Martín-Arana, Francisco Gimeno-Valiente

et al.

Cancer Treatment Reviews, Journal Year: 2023, Volume and Issue: 119, P. 102595 - 102595

Published: June 25, 2023

Cancer has become a global health issue and liquid biopsy emerged as non-invasive tool for various applications. In cancer, circulating tumor DNA (ctDNA) can be detected from cell-free (cfDNA) obtained plasma potential early diagnosis, treatment, resistance, minimal residual disease detection, tumoral heterogeneity identification. However, the low frequency of ctDNA requires techniques accurate analysis. Multitarget assay such Next Generation Sequencing (NGS) need improvement to achieve limits detection that identify variants present in cfDNA. this review, we provide general overview use cfDNA discuss developed optimize NGS detection. We also summarize results using strategies both investigational clinical contexts.

Language: Английский

Citations

22
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay DOI Creative Commons
Tadayoshi Hashimoto, Yoshiaki Nakamura, Eiji Oki

et al.

International Journal of Clinical Oncology, Journal Year: 2024, Volume and Issue: 29(5), P. 495 - 511

Published: March 29, 2024

Circulating tumor DNA (ctDNA) is the fraction of cell-free in patient blood that originates from a tumor. Advances sequencing technologies and our understanding molecular biology tumors have increased interest exploiting ctDNA to facilitate detection residual disease (MRD). Analysis as promising MRD biomarker solid malignancies has central role precision medicine initiatives exemplified by CIRCULATE-Japan project involving patients with resectable colorectal cancer. Notably, underscores prognostic significance status at 4 weeks post-surgery its correlation adjuvant therapy efficacy interim analysis. This substantiates hypothesis critical indicator relapse Despite remarkable advancements, challenges endure, primarily attributable exceedingly low concentration peripheral blood, particularly scenarios shedding intrinsic error rates current technologies. These complications necessitate more sensitive sophisticated assays verify clinical utility across all tumors. Whole genome (WGS)-based tumor-informed recently demonstrated ability detect parts-per-million range. review delineates landscape assays, highlighting WGS-based approaches forefront technique Additionally, it introduces upcoming endeavor, pan-cancer via ctDNA, forthcoming project, SCRUM-Japan MONSTAR-SCREEN-3.

Language: Английский

Citations

8
Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay DOI Creative Commons
Yoshiaki Nakamura, Yuichiro Tsukada, Nobuhisa Matsuhashi

et al.

Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 30(19), P. 4377 - 4387

Published: Aug. 7, 2024

Posttreatment detection of ctDNA is strongly predictive recurrence. Most minimal/molecular residual disease assays require prior tissue testing to guide analysis, resulting in lengthy time initial results and unevaluable patients.

Language: Английский

Citations

8